Background: The risk of recurrent herniation after lumbar discectomy is highest during the first postoperative year. The purpose of this study was to determine whether implantation of a bone-anchored annular closure device (ACD) following limited lumbar discectomy reduced the risk of recurrent herniation and complications during the first year of follow-up compared to limited lumbar discectomy alone (Controls) and whether this risk was influenced by patient characteristics.
Introduction
Recurrent lumbar disc herniation occurs in 7% to 18% of patients after lumbar discectomy. [1] [2] [3] Most recurrent cases require additional surgery to adequately resolve symptoms [4] yet the magnitude of clinical improvement after repeat surgery is less compared to primary surgery. [5, 6] Patients with large defects (≥6 mm width) in the annulus fibrosus after lumbar discectomy are particularly prone to reherniation and represent an under-served, high-risk subgroup. [4] The first postoperative year appears to be the most critical to long-term surgical success since pain recurs at a proportionally higher rate within 1 year of primary discectomy compared to during subsequent years. [7] Techniques intended to prevent reherniation and associated reoperations during this critical period have potential to significantly improve patient outcomes and may reduce medical costs since revision surgeries tend to be more expensive and technically demanding compared to primary procedures. [2, 8] Clinical outcomes during the first year after surgery are also important metrics utilized by healthcare payers for making coverage decisions on new medical technologies. A bone-anchored annular closure device (ACD) received marketing approval by the Food and Drug Administration in February 2019 for prevention of lumbar disc reherniation. An analysis of 1-year results with the ACD and determination of whether patient characteristics might influence clinical outcomes is warranted. The primary objective of this study was to determine if additional use of a bone-anchored ACD that is intended to occlude large postsurgical annular defects could reduce recurrence and complication rates in a high-risk patient population during the critical first year after limited lumbar discectomy. A secondary objective was to determine whether these risks were influenced by patient characteristics.
Methods

Trial design
This was a multicenter randomized trial with the primary objective to determine whether implantation of a bone-anchored ACD following lumbar discectomy (ACD group) reduced the risk of recurrent herniation compared to lumbar discectomy alone (Control group). Local ethics review boards approved the study and participants provided written informed consent. The study was prospectively registered at ClinicalTrials.gov (NCT01283438) and the study protocol was previously published. [9] 
Participants
Preoperative imaging tests included magnetic resonance imaging (MRI) with T1-and T2-weighted axial and sagittal images of the lumbar spine, low-dose multiplanar computed tomography (CT) of the target level only, and flexion/extension x-rays. Eligible patients presented with imaging evidence of lumbar disc herniation at a single level between L1 and S1. Radicular symptoms were confirmed by a positive straight leg raise or femoral stretch test. Patients reported leg pain severity at least 40/ 100 on a visual analogue scale and back-related dysfunction at least 40/100 on the Oswestry Disability Index (ODI) despite at least 6 weeks of attempted nonsurgical management. Important exclusion criteria were previous spinal surgery at the level of the herniation, spondylolisthesis with ≥25% slip, and lumbar osteoporosis. Patients who met all preoperative eligibility criteria were scheduled for limited lumbar discectomy during which the final eligibility criterion regarding annular defect size would be assessed. A complete list of eligibility criteria is provided in Table 1 .
Lumbar discectomy procedure
All patients were treated on an inpatient basis by experienced spine surgeons with limited lumbar microdiscectomy using an interlaminar transflaval approach as described by Spengler. [10] The limited disc excision procedure involved exposure of the ligamentum flavum and, if necessary, a small unilateral foraminotomy was performed to expose the affected disc space. Via an incision in the annulus fibrosus, disc material fragments in the extradiscal space on the affected side were removed with no or minimal removal of tissue fragments from the intervertebral disc space.
Intraoperative randomization
At completion of the limited discectomy procedure, patients were then evaluated for ACD eligibility by measuring the size of the annular defect. Patients with a large annular defect (4-6 mm tall and 6-10 mm wide) were randomly allocated (1:1) to ACD or Control groups using a central web-based system. Patients whose annular defects did not meet these size thresholds were excluded from further study participation. Patients assigned to the Control group received no additional treatment and the limited discectomy procedure was concluded in standard fashion.
Annular closure device and implantation procedure
Patients assigned to the ACD group received a permanent implant (Barricaid, Intrinsic Therapeutics) consisting of two Table 1 Inclusion and exclusion criteria. Inclusion criteria 1. Age 21 to 75 years and skeletally mature (male or female) 2. Posterior or posterolateral disk herniations at one level between L1 and S1 with confirmation of neural compression using MRI.[Note: Intraoperatively, only postdiskectomy anular defects between 4 and 6 mm tall and 6 and 10 mm wide shall qualify] 3. At least 6 weeks of failed, conservative treatment prior to surgery, including physical therapy, use of anti-inflammatory medications at maximum-specified dosage, and/or administration of epidural/facet injections 4. Minimum posterior disk height of 5 mm at the index level 5. Radiculopathy (with or without back pain) with positive straight leg raise (0 -60 degrees) (L4/5, L5/S1) or femoral stretch test (L1/2, L2/3, L3/4 only) 6. Oswestry Disability Index score of at least 40/100 at baseline 7. Visual analog scale leg pain (one or both legs) score of at least 40/100 at baseline 8. Psychosocially, mentally, and physically able to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements Exclusion criteria 1. Spondylolisthesis grade II or higher (25% slip or greater) 2. Requires spinal surgery other than a diskectomy (with or without laminotomy) to treat leg/back pain (scar tissue and osteophyte removal is allowed) 3. Back or non-radicular leg pain of unknown etiology 4. Prior surgery at the index lumbar vertebral level 5. Patients with a SCORE of 6 or greater and a subsequent spine DXA T-score less than -2.0 at the index level. For herniations at L5/S1, the average T-score of L1-L4 shall be used 6. Clinically compromised vertebral bodies in the lumbosacral region due to any traumatic, neoplastic, metabolic, or infectious pathology 7. Pathologic fractures of the vertebra or multiple fractures of the vertebra or hip 8. Scoliosis of greater than 10 degrees (both angular and rotational) 9. Any metabolic bone disease 10. Active infection, either systemic or local 11. Cauda equine syndrome or neurogenic bowel/bladder dysfunction 12. Severe arterial insufficiency of the legs or other peripheral vascular disease (Screening on physical examination for subjects with diminution or absence of dorsalis pedis or posterior tibialis pulses. If diminished or absent by palpation, then an arterial ultrasound is required with vascular plethysmography. Absolute arterial pressure below 50 mm Hg at the calf or ankle level results in exclusion.) 13. Significant peripheral neuropathy, defined as Type I or II diabetes or similar systemic metabolic condition causing decreased sensation in a stocking-like or non-radicular and non-dermatomal distribution in the lower extremities 14. Insulin-dependent diabetes mellitus 15. Morbidly obese, defined as a body mass index > 40 or weighing more than 100 lbs over ideal body weight 16. Active hepatitis, AIDS, or HIV 17. Rheumatoid arthritis or other autoimmune disease 18. Known allergy to titanium, polyethylene, or polyester materials 19. Baseline MRI cannot be obtained 20. Pregnant or interested in becoming pregnant in the next 3 years 21. Active tuberculosis or history of tuberculosis in the past 3 years 22. History of active malignancy, defined as any invasive malignancy, except nonmelanoma skin cancer, unless treated with curative intent with no signs or symptoms of malignancy for at least 2 years 23. Immunologically suppressed, defined as receiving steroids for more than 1 month over the past year 24. Current anticoagulation therapy other than aspirin, unless anticoagulation therapy may be suspended for surgery 25. Current chemical/alcohol dependency or significant psychosocial disturbance 26. Life expectancy of less than 3 years 27. Current involvement in active spinal litigation 28. Current involvement in another investigational study 29. Incarceration 30. Any contraindication for MRI or CT scan (e.g., claustrophobia, contrast allergy) van den Brink et al. Medicine (2019) 98:44 Medicine components-an occlusion component to block the annular defect and a titanium anchor to secure the occlusion component to an adjacent vertebral body (Fig. 1 ). The occlusion component is comprised of a flexible polymer that is designed to prevent reherniation by physically blocking the annulus at the post-surgery defect and maintaining hydrostatic pressure inside the nucleus pulposus, [11] and contains a platinum-iridium radiopaque marker to enable radiographic visualization. The anchor component is comprised of a sawtoothed titanium alloy that is carefully hammered into either the caudal-adjacent or cranial-adjacent vertebral body to resist migration. After confirmation of a large annular defect, a sizing trial was performed under fluoroscopic control to establish the correct position and angle of the ACD. Next, the device was implanted under fluoroscopic guidance by impacting the anchor into the vertebral body while the occlusion component was placed in the annular defect to prevent expulsion of disc material into the extradiscal space. After fluoroscopic confirmation of correct device placement, the surgical site was inspected and standard wound closure was performed.
Outcomes
Clinical follow-up occurred at 6 weeks, 3 months, 6 months, and 1-year follow-up, with imaging tests (CT, MRI, and flexionextension x-rays) performed at 1 year. Symptomatic reherniation was either confirmed during reoperation, or diagnosed based on an independent imaging core laboratory confirmation of reherniation combined with associated clinical symptoms. Reoperations included any surgical procedure that was performed at the level of the original herniation, regardless of side, during follow-up. The decision to reoperate was based on patient-physician shared decision-making. The occurrence of adverse events was evaluated at each visit and adjudicated for seriousness and relation to the procedure or device by an independent Data Safety Monitoring Board.
Statistical analysis
The sample size of this trial was determined using Bayesian techniques. Baseline patient characteristics were presented as means and standard deviations for continuous variables and counts and percentages for categorical variables. Baseline group comparisons were made with independent samples t test for continuous data or Fisher exact test for categorical data. We additionally reported the absolute standardized difference (ASD) statistic, which is calculated as the difference in means or proportions between groups divided by the pooled standard deviation. A small difference between treatment groups is defined as an ASD of less than 0.2. Time-to-event data were analyzed using Kaplan-Meier methods with log-rank tests for group comparisons. Cox regression models were developed for interaction testing to evaluate the consistency of treatment effects between patient characteristic subgroups. Statistical significance was set at P < .05 and hypothesis testing was twosided. Statistical analyses were performed using SAS v9.4 (SAS Institute).
Results
Patient characteristics and follow-up
Between December 2010 and October 2014, 554 patients were randomly allocated to ACD (n = 276) or Control (n = 278) groups. ACD implantation was not attempted in 4 patients due to proximity of the nerve root; these patients were excluded from the analysis. Randomization effectively balanced baseline patient characteristics between treatment groups, which were typical of the general population undergoing lumbar discectomy. Mean www.md-journal.com patient age was 43 years, 59% were male, and patients generally presented with severe leg pain and disability. The proportion of patients with herniation at L5-S1 was statistically higher in the Control group compared to the ACD group (P = .04), but the magnitude of this difference was small (ASD = .23) ( Table 2) . Patient compliance with follow-up visits was high in each group, with 94% returning for the 1-year visit (Fig. 2 ).
Symptomatic reherniation, reoperation, and complications
The benefit of the ACD in preventing symptomatic reherniation was realized soon after surgery and maintained throughout the 1year follow-up period. Over 1 year, the cumulative risk of experiencing a symptomatic reherniation was 8.4% in the ACD group and 17.3% in the Control group (P = .002) ( Fig. 3) . The corresponding hazard ratio was 0.45 (95% CI: 0.27, 0.75), indicating a 55% risk reduction with ACD. There was no modification of this risk estimate according to age (P = .11), sex (P = .82), body mass index (BMI) (P = .66), smoking status (P = .51), level of herniation (P = .12), leg pain severity at baseline (P = .64), or ODI at baseline (P = .82) (Fig. 4) .
The ACD was similarly efficacious in reducing the risk of reoperation with similar observation of early benefit that was maintained over 1 year. There were 21 reoperations in 18 ACD patients and 41 reoperations in 35 Control patients during this period. The cumulative risk of reoperation was 6.7% in the ACD group and 12.9% in the Control group (P = .015) (Fig. 5) . The corresponding hazard ratio was 0.50 (95% CI: 0.28, 0.88), indicating a 50% risk reduction with ACD. There was no modification of this risk estimate according to age (P = .21), sex (P = .64), BMI (P = .38), smoking status (P = .43), level of herniation (P = .26), leg pain severity at baseline (P = .39), or ODI at baseline (P = .54) ( Fig. 6) .
Implantation of the ACD was unsuccessful in 5 patients, including 4 patients in whom the flexible polymer component did not fully enter the disc and in 1 patient with nerve root injury during attempted implantation. The cumulative risk of a procedure-or device-related serious adverse event over 1 year was 7.1% for ACD and 13.9% for Controls (P = .009) (Fig. 7) . The corresponding hazard ratio was 0.49 (95% CI: 0.28, 0.85), indicating a 51% risk reduction with ACD. There was no modification of this risk estimate according to age (P = .10), sex (P > .99), BMI (P = .36), smoking status (P = .77), level of herniation (P = .17), leg pain severity at baseline (P = .85), or ODI at baseline (P = .52) ( Fig. 8) . This difference was primarily due to the lower incidence of symptomatic reherniation in the ACD group. Comparing the ACD to Control group across subcategories of procedure-or devicerelated serious adverse events, the corresponding frequencies were 0% vs 0.7% for cardiac/vascular, 2.2% vs 0% for device deficiency, 3.7% for 12.9% for disc herniation, 0.4% vs 0% for neurological, 1.5% vs 0.7% for pain, and 1.1% vs 1.8% for wound complications.
The percentage of patients experiencing symptomatic reherniation, reoperation, or a procedure-or device-related serious adverse event over 1 year was 11.2% for ACD and 20.9% for Controls (P = .002). The corresponding hazard ratio was 0.50 (95% CI: 0.32, 0.78), indicating a 50% risk reduction with ACD.
Discussion
Lumbar herniation recurrence remains a challenging therapeutic problem, particularly in the high-risk subset of patients with a large defect in the annulus fibrosus following lumbar discectomy. This randomized trial was designed specifically to determine whether recurrence risk could be lowered by additional implantation of a device that physically occludes the defect in the annulus following surgery. During the first postoperative year when recurrence risk is the greatest, patients who received lumbar discectomy with bone-anchored ACD implantation had a lower risk of symptomatic reherniation, reoperation, and serious adverse events compared to patients treated with lumbar discectomy only. Further, the treatment benefit of the ACD was realized early, was durably maintained, and was not influenced by baseline patient characteristics. These results have The results reported here are in agreement with a recent metaanalysis that reported annular closure resulted in a 66% reduction in the risk of symptomatic reherniation. [12] An interesting aspect of these results was the almost immediate benefit derived in the ACD group relative to Controls. For example, in the first 30 days after surgery, only 1 patient suffered symptomatic reherniation in the ACD group compared to 7 patients in the Control group. Notably, the benefits of ACD were derived without an increase in associated serious complications and, thus, the benefit-to-risk profile of this device appears favorable in well-selected patients.
There is mounting evidence that additional implantation of a bone-anchored ACD implantation is cost effective in high-risk patients relative to lumbar discectomy alone. Parker and colleagues reported that direct and indirect medical costs associated with the management of recurrent disc herniation totaled approximately $38,000 per case and that bone-anchored ACD use resulted in a $2,200 savings per person compared to discectomy alone. [13] More recently, Ament and colleagues [14] derived similar conclusions in which lumbar discectomy with ACD was $2,100 less expensive than with discectomy alone. Further, patients treated with ACD reported better health-related quality of life. Thus, in the context of a health economics evaluation, the ACD was deemed dominant in which greater quality of life was attained at less cost. Although evaluation of medical costs incurred over 1 year of follow-up are beyond the scope of this paper, the risk reductions in symptom recurrence, reoperations, and serious complications suggest potential for cost It is important to note that careful patient selection is mandatory when considering treatment with an ACD. Patients with small postsurgical annular defects are poor candidates for treatment with the ACD since reherniation risk in such patients is comparatively low. [4] Posterior disc height must be at least 5 mm to accommodate device placement. Patients with lumbar osteoporosis, spinal malignancy, or significant metabolic bone disease may not have adequate bone stock to facilitate sufficient device purchase into the adjacent vertebral body. Meticulous surgical technique is also a prerequisite for safe device placement. The ACD should not be implanted if the location of the nerve root prevents delivery of the anchor. Also, surgical instrument alignment under fluoroscopic guidance prior to ACD implantation allows the surgeon to select the correct implantation trajectory, which may lower the risk for complications due to device malpositioning. Attention to these patient-and procedurerelated recommendations is mandatory in order to ensure patient safety and optimize clinical efficacy. Strengths of the trial design included data monitoring, safety oversight by an independent committee, adverse event adjudication, and independent imaging review. There were also several aspects of this study that may be considered limitations. First, this report was focused on results during the first postoperative year since the risk of herniation recurrence is greatest during this period. Thus, the influence of patient characteristics on long-term results remains unclear. Second, all patients were treated with limited lumbar discectomy and, therefore, it is plausible that aggressive disc resection may also lower reherniation rates albeit at the risk of developing intervertebral instability and acceleration of spondylosis. [15] Third, approximately 1 in 3 patients have a large annular defect after lumbar discectomy [4] and, therefore, ACD implantation is only appropriate in this high-risk subset of the population undergoing lumbar discectomy. Patients with annular defect widths greater than 10 mm were not studied due to device size limitations. Finally, it is plausible that baseline patient characteristics had a small influence on the risk of symptomatic reherniation and reoperation risk with ACD since the study was not prospectively designed for these subgroup comparisons.
Among patients with large annular defects following limited lumbar discectomy, additional implantation with a bone-anchored ACD lowered the risk of symptomatic reherniation and reoperation over 1-year follow-up. Device-or procedure-related serious adverse events occurred less frequently in the ACD group. These conclusions were not influenced by patient characteristics. 
